Benefits of recombinant thyroid stimulating hormone (rhTSH) in thyroid cancer follow-up
Pichon Riviere A, Augustovski F, Cernadas C, Ferrante D, Regueiro A, Garcia Marti S
Record ID 32005000660
Spanish
Authors' objectives:
This study aims to provide an overview of the benefits of recombinant thyroid stimulating hormone (rhTSH) in thyroid cancer follow-up.
Authors' results and conclusions:
Since approved by the FDA market use, there has been scarce and poor evidence that compares this test diagnostic performance with other follow-up standards. However, comparative designs evaluated suggest that rhTSH would not be better than thyroglobulin dosage and traditional I131 uptake test.
Authors' recommendations:
Due to this and its high cost, indication should be restricted to those patients where hormone replacement therapy suppression is contraindicated.
Authors' methods:
Overview
Details
Project Status:
Completed
URL for project:
http://www.iecs.org.ar/
Year Published:
2004
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Argentina
MeSH Terms
- Recombinant Proteins
- Thyroglobulin
- Thyroid Neoplasms
- Thyrotropin
Contact
Organisation Name:
Institute for Clinical Effectiveness and Health Policy
Contact Address:
Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name:
info@iecs.org.ar
Contact Email:
info@iecs.org.ar
Copyright:
Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.